Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor): Update of Safety Review The
FDA has completed its review of the final clinical study report of ENHANCE and issued an update.
Source: www.fda.govMoredun Scientific Launches Biosafety Testing Services, Scotland Moredun Scientific Ltd has launched a portfolio of GLP/GMP compliant biosafety testing services to support the biopharmaceutical industry through testing of final products and in-process materials for human and veterinary use. A range of microbiology and virology services, including in vivo assays, are provided to clients. All tests are conducted to meet international regulatory requirements governing the manufacture and quality control of biopharmaceuticals.
Source: www.medicalnewstoday.comUS Pharmacopeia Announces New Standards To Protect Patients From Counterfeit And Adulterated Medicines With counterfeit and adulterated medicines posing an increasing risk to patients in the United States and worldwide, the U.S. Pharmacopeial (USP) Convention today announces new standards for two widely used drug products that have been involved in episodes of adulteration resulting in patient deaths. The release of these standards, for the blood thinner heparin and the sweetener glycerin, comes on the heels of recent and dangerous incidents involving the two products.
Source: www.medicalnewstoday.comBoston Globe Examines Debate Over Cost Effectiveness Of Mail-Order Pharmacies Some mail-order
pharmacy owners have told the Obama administration that Medicare spending could be reduced and quality could be improved if more beneficiaries ordered their medications by mail, the Boston Globe reports.
Source: www.medicalnewstoday.comCanada Needs A National Pharmaceuticals Strategy Canada needs a national strategy to ensure broad access to
prescription drugs, yet plans for a strategy have stalled. Compared with many other countries, Canada lags behind in
prescription access and affordability, quality and safety of medication use. A commentary in CMAJ makes the case for reigniting a strategy to benefit Canadians.
Source: www.medicalnewstoday.comVIVUS Initiates Avanafil Phase 3 Trials For Males With Erectile Dysfunction VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced it has initiated the first of several pivotal phase 3 studies of avanafil, our investigational product for the treatment of erectile dysfunction (ED). Avanafil is a next-generation, fast-acting, selective, investigational oral phosphodiesterase type 5 (PDE5) inhibitor.
Source: www.medicalnewstoday.comTopical Anesthetics Patients, healthcare professionals, and caregivers alerted to serious hazards of using skin numbing products for relieving pain from mammography and other medical tests and conditions, especially when applied to a large area of skin or when the area of application is covered.
Source: www.fda.govPharmacists To Get Access To Patients' Electronic Records, UK Pharmacists will gain access to the Summary Care Record for the first time under plans by NHS IT managers, Pulse can reveal. Pilots are being considered in community pharmacies across the country, as a key step in the Government drive for pharmacies to take on more clinical work.
Source: www.medicalnewstoday.comA Clear Explanation Of Prescription Pricing Many Australians do not understand the complex pricing system for
prescription medicines. If you've ever asked "How much will my
prescription cost?" and were bamboozled by the answer, you are not alone. In the latest edition of Australian Prescriber, Michael Tatchell, Health Economics Director of the
Pharmacy Guild of Australia, explains the pricing structure of government-subsidised medicines.
Source: www.medicalnewstoday.com
# posted by Network @ 10:51 AM
